Literature DB >> 27528547

The role of systemic steroids and phototherapy in the treatment of stable vitiligo: a randomized controlled trial.

Medhat El Mofty1, Samia Essmat1, Randa Youssef1, Sherine Sobeih1, Doaa Mahgoub1, Sherine Ossama1, Akmal Saad1, Amira El Tawdy1, Heba M Mashaly1, Iman Saney1, Rana Helal1, Olfat Shaker1.   

Abstract

Pathogenesis of vitiligo is believed to be multifactorial disease with a wide variety of therapeutic modalities. The aim of this work is to assess the efficacy of oral mini-pulse steroids (OMP) plus Nb-U.V.B in comparison to OMP alone and Nb-U.V.B alone in treating stable vitiligo. A prospective randomized controlled study including 45 patients categorized into three groups receiving therapy for 3 months; Group A received Nb-U.V.B plus OMP, Group B received OMP alone while Group C received Nb-U.V.B alone. Clinical assessment and PCR evaluation of bFGF, ICAM1, and ELISA for AMA were done. Patients receiving Nb-U.V.B plus OMP and using Nb-U.V.B alone gave statistically significant clinical response than those treated with OMP alone. Statistically significant rise of BFGF was noticed after treatment with Nb-U.V.B plus OMP and with Nb-U.V.B alone. Patients treated with OMP alone and with Nb-U.V.B alone showed statistically significant drop of ICAM-1 after therapy. NB-U.V.B plus OMP and Nb-U.V.B alone were found to be clinically superior over OMP alone in treating stable vitiligo patients, hence suggesting that adding OMP to Nb-U.V.B can maintain clinical and laboratory success for a longer period of time and with less relapse.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  NB-U.V.B; oral pulse steroids; systemic steroids; vitiligo

Mesh:

Substances:

Year:  2016        PMID: 27528547     DOI: 10.1111/dth.12384

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  3 in total

Review 1.  [Systemic treatment of vitiligo : Balance and current developments].

Authors:  M Meurer; P Ceric-Dehdari
Journal:  Hautarzt       Date:  2017-11       Impact factor: 0.751

Review 2.  Clinical and Molecular Aspects of Vitiligo Treatments.

Authors:  Anuradha Bishnoi; Davinder Parsad
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

Review 3.  Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.

Authors:  Feras M Ghazawi; Megan Lim; Jan P Dutz; Mark G Kirchhof
Journal:  Int J Dermatol       Date:  2020-07-03       Impact factor: 2.736

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.